T. Rowe Price Associates
ACOR

T. Rowe Price Associates’s Acorda Therapeutics ACOR Stock Holding History

T. Rowe Price Associates’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,219
Closed -$137K – 2739
2020
Q3 		$137K Hold
2,219
– – ﹤0.01% 2491
2020
Q2 		$196K Sell
2,219
-24
-1% -$2.54K ﹤0.01% 2358
2020
Q1 		$251K Buy
2,243
+393
+21% +$77.4K ﹤0.01% 2249
2019
Q4 		$453K Buy
1,850
+1,674
+951% +$422K ﹤0.01% 2182
2019
Q3 		$61K Buy
176
+2
+1% +$1.09K ﹤0.01% 2481
2019
Q2 		$161K Buy
174
+1
+0.6% +$1.23K ﹤0.01% 2432
2019
Q1 		$276K Buy
173
+1
+0.6% +$1.8K ﹤0.01% 2321
2018
Q4 		$322K Sell
172
-2,584
-94% -$5.62M ﹤0.01% 2254
2018
Q3 		$6.5M Buy
2,756
+27
+1% +$83.6K ﹤0.01% 1433
2018
Q2 		$9.4M Buy
2,729
+704
+35% +$2.16M ﹤0.01% 1353
2018
Q1 		$5.75M Buy
2,025
+544
+37% +$1.63M ﹤0.01% 1414
2017
Q4 		$3.81M Sell
1,481
-313
-17% -$890K ﹤0.01% 1460
2017
Q3 		$5.09M Buy
1,794
+283
+19% +$746K ﹤0.01% 1437
2017
Q2 		$3.57M Sell
1,511
-3,406
-69% -$6.75M ﹤0.01% 1459
2017
Q1 		$12.4M Sell
4,917
-53
-1% -$153K ﹤0.01% 1288
2016
Q4 		$11.2M Sell
4,970
-1,024
-17% -$2.43M ﹤0.01% 1293
2016
Q3 		$15M Buy
5,994
+4,559
+318% +$13.6M ﹤0.01% 1221
2016
Q2 		$4.39M Sell
1,435
-4
-0.3% -$13K ﹤0.01% 1411
2016
Q1 		$4.57M Buy
1,439
+44
+3% +$183K ﹤0.01% 1413
2015
Q4 		$7.16M Buy
1,395
+327
+31% +$1.43M ﹤0.01% 1355
2015
Q3 		$3.4M Sell
1,068
-1,621
-60% -$6.29M ﹤0.01% 1487
2015
Q2 		$10.8M Sell
2,689
-33
-1% -$127K ﹤0.01% 1328
2015
Q1 		$10.9M Buy
2,722
+134
+5% +$614K ﹤0.01% 1319
2014
Q4 		$12.7M Buy
2,588
+16
+0.6% +$68.7K ﹤0.01% 1257
2014
Q3 		$10.5M Buy
2,572
+3
+0.1% +$11.3K ﹤0.01% 1297
2014
Q2 		$10.4M Sell
2,569
-5
-0.2% -$20.4K ﹤0.01% 1306
2014
Q1 		$11.7M Sell
2,574
-14
-0.5% -$56.6K ﹤0.01% 1263
2013
Q4 		$9.07M Sell
2,588
-116
-4% -$452K ﹤0.01% 1311
2013
Q3 		$11.1M Buy
2,704
+7
+0.3% +$30.2K ﹤0.01% 1241
2013
Q2 		$10.7M Buy
+2,697
New +$11.1M ﹤0.01% 1229

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

T. Rowe Price Associates's ACOR Position: Q4 2020 in Review

T. Rowe Price Associates sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 2,219 shares — an estimated $137K sold.

T. Rowe Price Associates first reported a position in ACOR in Q2 2013 and held it in 30 quarters. The position peaked at $15M in Q3 2016. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • T. Rowe Price Associates reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,219 Acorda Therapeutics shares in Q4 2020, an estimated $137K.
  • T. Rowe Price Associates first reported a position in Acorda Therapeutics in Q2 2013 and held it in 30 quarters.
  • T. Rowe Price Associates's Acorda Therapeutics position peaked at $15M in Q3 2016.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.